Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowShares of Eli Lilly and Co. rose as much as 4.6 percent on Feb. 19 after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large Phase 3 trial.
When ramucirumab was applied to non-small-cell lung cancer, along with a traditional chemotherapy drug, it showed a statistically significant extension of the time of overall survival when compared with patients who took only the chemotherapy drug, Lilly said.
Some patients receiving ramucirumab experienced decreased white blood cell count, fatigue and hypertension.
Lilly’s stock price rose to as high as $57.78 in Feb. 19 trading.
Lilly said it would release more detailed results later this year at a scientific conference. Lilly also plans to submit ramucirumab for market approval with the U.S. Food and Drug Administration later this year. The drug has already shown positive results as a treatment for gastric cancer, and Lilly is studying the drug as a liver cancer treatment as well.
Please enable JavaScript to view this content.